Publications

PetMedicus Laboratories Receives MUMS Designation for Ondansetron (VML-028) in Cisplatin-Induced Emesis.
View post
, or download PDF.

EVALUATION OF THE ORAL ANTIMITOTIC, ABT-751, ALONE AND IN COMBINATION AN ANTIANGIOGENIC PEPTIDE OF THROMBOSPONDIN-1, ABT-510, IN DOGS WITH LYMPHOMA.
View post
, or download PDF.

A randomized placebo-controlled clinical trial of the anti-angiogenic thromobspondin-mimetic peptide ABT-526 plus Lomustine chemotherapy versus Lomustine chemotherapy alone in pet dogs with relapsed non-Hodgkin’s lymphoma.
View post, or download PDF.

A Randomized Placebo-Controlled Clinical Trial of ABT-526 Antiangiogenic Therapy Plus Lomustine Chemotherapy Versus Lomustine Chemotherapy Alone in Dogs With Relapsed Lymphoma.
View post
, or download PDF.

Antiangiogenic Thrombospondin-I peptides result in regression of naturally occurring cancers in pet dogs.
View post
, or download PDF. Also, download a large, full-color PDF poster of this publication.

Tumor inhibition by antiangiogenic TSP-I mimetic peptides.
View post
.

A new option for the treatment of canine lymphoma.
View post
, or download PDF.

Targeting the blood supply of cancer.
View post
, or download PDF.

Ongoing evaluation of single agent thalidomide in dogs with measurable cancer.
View post
, or download PDF.